• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

连接的Toll样受体激动剂刺激不同的、依赖组合的固有免疫反应。

Linked Toll-Like Receptor Triagonists Stimulate Distinct, Combination-Dependent Innate Immune Responses.

作者信息

Albin Tyler J, Tom Janine K, Manna Saikat, Gilkes Adrienne P, Stetkevich Samuel A, Katz Benjamin B, Supnet Medalyn, Felgner Jiin, Jain Aarti, Nakajima Rie, Jasinskas Algis, Zlotnik Albert, Pearlman Eric, Davies D Huw, Felgner Phillip L, Burkhardt Amanda M, Esser-Kahn Aaron P

机构信息

Department of Chemistry, University of California, Irvine, California 92617, United States.

Pritzker School of Molecular Engineering, University of Chicago, Chicago, Illinois 60637, United States.

出版信息

ACS Cent Sci. 2019 Jul 24;5(7):1137-1145. doi: 10.1021/acscentsci.8b00823. Epub 2019 Jun 27.

DOI:10.1021/acscentsci.8b00823
PMID:31403067
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6661867/
Abstract

Traditional vaccination strategies have failed to generate effective vaccines for many infections like tuberculosis and HIV. New approaches are needed for each type of disease. The protective immunity and distinct responses of many successful vaccines come from activating multiple Toll-like receptors (TLRs). Vaccines with multiple TLRs as adjuvants have proven effective in preclinical studies, but current research has not explored two important elements. First, few multi-TLR systems explore spatial organization-a critical feature of whole-cell vaccines. Second, no multi-TLR systems to date provide systematic analysis of the combinatorial space of three TLR agonists. Here, we present the first examination of the combinatorial space of several spatially defined triple-TLR adjuvants, by synthesizing a series of five triple-TLR agonists and testing their innate activity both and . The combinations were evaluated by measuring activation of immune stimulatory genes (Nf-κB, ISGs), cytokine profiles (IL12-p70, TNF-α, IL-6, IL-10, CCL2, IFN-α, IFN-β, IFN-γ), and cytokine serum levels (IL-6, TNF-α, IL12-p40, IFN-α, IFN-β). We demonstrate that linking TLR agonists substantially alters the resulting immune response compared to their unlinked counterparts and that each combination results in a distinct immune response, particularly between linked combinations. We show that combinations containing a TLR9 agonist produce more Th1 biasing immune response profiles, and that the effect is amplified upon conjugation. However, combinations containing TLR2/6 agonist are skewed toward T2 biasing profiles despite the presence of TLR9. These results demonstrate the profound effects that conjugation and combinatorial administration of TLR agonists can have on immune responses, a critical element of vaccine development.

摘要

传统的疫苗接种策略未能为许多感染性疾病(如结核病和艾滋病)研发出有效的疫苗。针对每种疾病都需要新的方法。许多成功疫苗的保护性免疫和独特反应来自于激活多种Toll样受体(TLR)。以多种TLR作为佐剂的疫苗在临床前研究中已被证明是有效的,但目前的研究尚未探索两个重要因素。首先,很少有多TLR系统探索空间组织——这是全细胞疫苗的一个关键特征。其次,迄今为止,没有多TLR系统对三种TLR激动剂的组合空间进行系统分析。在这里,我们通过合成一系列五种三联TLR激动剂并在体外和体内测试它们的天然活性,首次对几种空间定义的三联TLR佐剂的组合空间进行了研究。通过测量免疫刺激基因(Nf-κB、ISGs)的激活、细胞因子谱(IL12-p70、TNF-α、IL-6、IL-10、CCL2、IFN-α、IFN-β、IFN-γ)以及细胞因子血清水平(IL-6、TNF-α、IL12-p40、IFN-α、IFN-β)来评估这些组合。我们证明,与未连接的对应物相比,连接TLR激动剂会显著改变产生的免疫反应,并且每种组合都会产生独特的免疫反应,特别是在连接组合之间。我们表明,含有TLR9激动剂的组合会产生更多偏向Th1的免疫反应谱,并且在偶联后这种效果会增强。然而,尽管存在TLR9,但含有TLR2/6激动剂的组合却偏向T2偏向谱。这些结果证明了TLR激动剂的偶联和组合给药对免疫反应可能产生的深远影响,而免疫反应是疫苗开发的关键要素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/671bd9119682/oc-2018-00823q_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/e100d8c8e6c4/oc-2018-00823q_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/060182445bcc/oc-2018-00823q_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/baca718e402f/oc-2018-00823q_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/007b35b43f57/oc-2018-00823q_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/671bd9119682/oc-2018-00823q_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/e100d8c8e6c4/oc-2018-00823q_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/060182445bcc/oc-2018-00823q_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/baca718e402f/oc-2018-00823q_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/007b35b43f57/oc-2018-00823q_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a4d/6661867/671bd9119682/oc-2018-00823q_0005.jpg

相似文献

1
Linked Toll-Like Receptor Triagonists Stimulate Distinct, Combination-Dependent Innate Immune Responses.连接的Toll样受体激动剂刺激不同的、依赖组合的固有免疫反应。
ACS Cent Sci. 2019 Jul 24;5(7):1137-1145. doi: 10.1021/acscentsci.8b00823. Epub 2019 Jun 27.
2
TLR agonist combinations that stimulate Th type I polarizing responses from human neonates.刺激人类新生儿 Th 型 I 极化反应的 TLR 激动剂组合。
Innate Immun. 2018 May;24(4):240-251. doi: 10.1177/1753425918771178. Epub 2018 Apr 19.
3
Modulation of Innate Immune Responses Covalently Linked TLR Agonists.天然免疫反应的调节 共价连接的Toll样受体激动剂
ACS Cent Sci. 2015 Nov 25;1(8):439-448. doi: 10.1021/acscentsci.5b00274. Epub 2015 Oct 28.
4
Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses.Toll样受体(TLR)2-9激动剂诱导的细胞因子和趋化因子:I. 与T细胞受体诱导反应的比较。
Cell Immunol. 2006 Sep;243(1):48-57. doi: 10.1016/j.cellimm.2006.12.002. Epub 2007 Jan 23.
5
[Frontier of mycobacterium research--host vs. mycobacterium].[分枝杆菌研究前沿——宿主与分枝杆菌]
Kekkaku. 2005 Sep;80(9):613-29.
6
TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha.人外周血单核细胞中Toll样受体(TLR)之间的相互作用导致1型和2型干扰素、白细胞介素-12和肿瘤坏死因子-α的协同和拮抗调节。
Int Immunopharmacol. 2007 Aug;7(8):1111-21. doi: 10.1016/j.intimp.2007.04.006. Epub 2007 May 4.
7
Toll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sézary syndrome.Toll样受体激动剂可部分恢复蕈样肉芽肿综合征中促炎细胞因子和I型干扰素的产生。
Oncotarget. 2016 Nov 15;7(46):74592-74601. doi: 10.18632/oncotarget.12816.
8
In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant.人血液中TLR激活疫苗佐剂的体外细胞因子诱导因年龄和佐剂而异。
Cytokine. 2016 Jul;83:99-109. doi: 10.1016/j.cyto.2016.04.001. Epub 2016 Apr 12.
9
Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.聚合物类病原体样颗粒协同递呈双重和三重 TLR 激动剂可显著增强固有和适应性免疫应答。
Sci Rep. 2017 May 31;7(1):2530. doi: 10.1038/s41598-017-02804-y.
10
Dectin-1 activation unlocks IL12A expression and reveals the TH1 potency of neonatal dendritic cells.Dectin-1 的激活可释放 IL12A 的表达,并揭示了新生儿树突状细胞的 TH1 潜能。
J Allergy Clin Immunol. 2015 Nov;136(5):1355-68.e1-15. doi: 10.1016/j.jaci.2015.02.030. Epub 2015 Apr 10.

引用本文的文献

1
Toll-like Receptor (TLR) Response in Chikungunya Virus Infection: Mechanism of Activation, Immune Evasion, and Use of TLR Agonists in Vaccine Development.基孔肯雅病毒感染中的Toll样受体(TLR)反应:激活机制、免疫逃逸以及TLR激动剂在疫苗开发中的应用
Vaccines (Basel). 2025 Aug 13;13(8):856. doi: 10.3390/vaccines13080856.
2
Co-delivery of antigen and adjuvant by site-specific conjugation to dendritic cell-targeted Fab fragments potentiates T cell responses.通过与树突状细胞靶向性Fab片段进行位点特异性偶联来共同递送抗原和佐剂,可增强T细胞反应。
RSC Chem Biol. 2025 May 5. doi: 10.1039/d5cb00014a.
3
Toll-like receptor response to Zika virus infection: progress toward infection control.

本文引用的文献

1
The Content of CpG-DNA in Antigen-CpG Conjugate Vaccines Determines Their Cross-Presentation Activity.抗原-CpG 偶联疫苗中的 CpG-DNA 含量决定了其交叉呈递活性。
Bioconjug Chem. 2019 Mar 20;30(3):561-567. doi: 10.1021/acs.bioconjchem.9b00091. Epub 2019 Feb 15.
2
Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.双 TLR 激动剂纳米盘作为疫苗和免疫疗法的强佐剂系统。
J Control Release. 2018 Jul 28;282:131-139. doi: 10.1016/j.jconrel.2018.04.041. Epub 2018 Apr 25.
3
Toll-like Receptor Agonist Conjugation: A Chemical Perspective.
Toll样受体对寨卡病毒感染的反应:感染控制方面的进展
Npj Viruses. 2025 Mar 13;3(1):20. doi: 10.1038/s44298-025-00102-3.
4
Co-Delivery of Multiple Toll-Like Receptor Agonists and Avian Influenza Hemagglutinin on Protein Nanoparticles Enhances Vaccine Immunogenicity and Efficacy.蛋白纳米颗粒上多种Toll样受体激动剂与禽流感血凝素的共递送增强疫苗免疫原性和效力。
Adv Healthc Mater. 2025 Apr;14(10):e2404335. doi: 10.1002/adhm.202404335. Epub 2025 Feb 9.
5
Linker Chemistry and Connectivity Fine-Tune the Immune Response and Kinetic Solubility of Conjugated NOD2/TLR7 Agonists.连接化学和连接性精细调节共轭 NOD2/TLR7 激动剂的免疫反应和动力学溶解度。
Bioconjug Chem. 2024 Nov 20;35(11):1723-1731. doi: 10.1021/acs.bioconjchem.4c00321. Epub 2024 Oct 10.
6
Safety and efficacy of toll-like receptor agonists as therapeutic agents and vaccine adjuvants for infectious diseases in animals: a systematic review.Toll样受体激动剂作为动物传染病治疗药物和疫苗佐剂的安全性和有效性:一项系统综述
Front Vet Sci. 2024 Sep 17;11:1428713. doi: 10.3389/fvets.2024.1428713. eCollection 2024.
7
Carbohydrate-Lectin Interactions Reprogram Dendritic Cells to Promote Type 1 Anti-Tumor Immunity.碳水化合物-凝集素相互作用重塑树突状细胞以促进 1 型抗肿瘤免疫。
ACS Nano. 2024 Oct 1;18(39):26770-26783. doi: 10.1021/acsnano.4c07360. Epub 2024 Sep 16.
8
Glycan-costumed virus-like particles promote type 1 anti-tumor immunity.聚糖包裹的病毒样颗粒促进1型抗肿瘤免疫。
bioRxiv. 2024 Jan 18:2024.01.18.575711. doi: 10.1101/2024.01.18.575711.
9
TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview.Toll样受体激动剂作为预防病毒感染的疫苗佐剂:概述
Front Microbiol. 2023 Dec 21;14:1249718. doi: 10.3389/fmicb.2023.1249718. eCollection 2023.
10
Multivalent vaccines demonstrate immunogenicity and protect against aerosol challenge.多价疫苗具有免疫原性,并能预防气溶胶挑战。
Front Immunol. 2023 Jul 18;14:1192821. doi: 10.3389/fimmu.2023.1192821. eCollection 2023.
toll 样受体激动剂缀合:化学视角。
Bioconjug Chem. 2018 Mar 21;29(3):587-603. doi: 10.1021/acs.bioconjchem.7b00808. Epub 2018 Feb 16.
4
Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.生物共轭方法生产由蛋白质或肽抗原和共价连接的 Toll 样受体配体组成的亚单位疫苗。
Bioconjug Chem. 2018 Mar 21;29(3):572-586. doi: 10.1021/acs.bioconjchem.7b00478. Epub 2017 Sep 22.
5
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy.新型佐剂设计用于提高疫苗效力概述。
Trends Pharmacol Sci. 2017 Sep;38(9):771-793. doi: 10.1016/j.tips.2017.06.002. Epub 2017 Jun 28.
6
Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.聚合物类病原体样颗粒协同递呈双重和三重 TLR 激动剂可显著增强固有和适应性免疫应答。
Sci Rep. 2017 May 31;7(1):2530. doi: 10.1038/s41598-017-02804-y.
7
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.小分子作为多 Toll 样受体激动剂的发现及其在促炎和抗癌活性方面的作用。
J Med Chem. 2017 Jun 22;60(12):5029-5044. doi: 10.1021/acs.jmedchem.7b00419. Epub 2017 Jun 6.
8
Immune Response Modulation of Conjugated Agonists with Changing Linker Length.连接子长度变化的共轭激动剂的免疫反应调节
ACS Chem Biol. 2016 Dec 16;11(12):3347-3352. doi: 10.1021/acschembio.6b00895. Epub 2016 Oct 25.
9
Toll-like receptors: the swiss army knife of immunity and vaccine development. toll 样受体:免疫和疫苗开发的瑞士军刀。
Clin Transl Immunology. 2016 May 20;5(5):e85. doi: 10.1038/cti.2016.22. eCollection 2016 May.
10
Beyond antigens and adjuvants: formulating future vaccines.超越抗原和佐剂:未来疫苗的配方设计
J Clin Invest. 2016 Mar 1;126(3):799-808. doi: 10.1172/JCI81083.